Slides
Page 1
Investors deckFebruary 2026
Page 2
Forward Looking Statement This presentation of PolyPid Ltd. (the “Company”) contains “forward-looking statements” within the meaning of the Private SecuritiesLitigation Reform Act and other securities laws. Words such as“expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,”“estimates” and similar expressions or variations of such words areintended to identify forward-looking statements. For example, theCompany is using forward-looking statements when it discussesstatements relating to our objectives, plans, and strategies, theexpected timing of trials, the research, development, and use of ourplatform technologies, technologies, products and productcandidates, potential benefits and advantages of our products andproduct candidates, and all statements (other than statements ofhistorical facts) that address activities, events, or developments thatthe Company intends, expects, projects, believes, or anticipates willor may occur in the future, the safety, efficacy and benefits of D-PLEx100 ,the expected timing for NDA submission, FDA acceptanceletter and PDUFA date, submission for NTAP reimbursement, EUsubmission, FDA approval and EU approval and US addressablemarket. Forward-looking statements are not historical facts, and arebased upon management’s current expectations, beliefs andprojections, many of which, by their nature, are inherently uncertain.Such expectations, beliefs and projections are expressed in goodfaith. However, there can be no assurance that management’sexpectations, beliefs and projections will be achieved and actualresults may differ materially from what is expressed in or indicatedby the forward-looking statements. Forward-looking statements aresubject to risks and uncertainties that could cause actualperformance or results to differ materially from those expressed inthe forward-looking statements. For a more detailed description ofthe risks and uncertainties affecting the Company, reference is madeto the Company’s reports filed from time to time with the Securitiesand Exchange Commission (“SEC”), including, but not limited to, therisks detailed in the Company’s Annual Report on Form 20-F, filedwith the SEC on February 26, 2025. Forward-looking statementsspeak only as of the date the statements are made. The Companyassumes no obligation to update forward-looking statements toreflect actual results, subsequent events or circumstances, changesin assumptions or changes in other factors affecting forward-lookinginformation except to the extent required by applicable securitieslaws. If the Company does update one or more forward-lookingstatements, no inference should be drawn that the Company willmake additional updates with respect thereto or with respect toother forward-looking statements.2
Page 3
Lead ProductD-PLEX100achieved 60% reduction in SSI in Phase 3 trial Company Snapshot 3 PolyPid is an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins. HQIsrael and U.S. Patents176* granted & pending Employees75*employees Core TechnologyKynatrix Long-Acting, Controlled-Release Technology Unique ValueCustomizable controlled release, linear delivery of APIs Next big opportunityUltra long GLP-1 Receptor Agonist *As of February 2026 Built for Scale GMP-certified 18,000 sq ft commercial-ready facility
Page 4
Introducing The PLEX Platform 4 Drug molecules are embedded within the alternating polymer-lipid layersBody moisture activates the platform, triggering controlled surface degradation of the polymer-lipid matrix and constant, linear drug release.Release is sustained and customizable for days to weeks
Page 5
The Power of Uncompromising Precision 5 Zero-Burst ReleaseNo initial drug spikeCustomizable DurationTunable from several days to several weeks.Layered Matrix ArchitectureControlled sequential disintegration. Scalable Manufacturing ProcessDesigned for consistent quality and commercial-scale production.Minimal Systemic ExposureReduced toxicity and side effects.Substance VersatilitySuitable for antibiotics, cytotoxic agents, peptides, nucleic acids, and more.
Page 6
Indication for UsePrevention of surgical site infections (SSIs) following abdominal colorectal surgery. Prevalence: 15%–25% in abdominal surgeryColorectal surgery, large incisions, and patients with obesity, diabetes, or immunocompromised have a higher risk of infection. What is it?A high-concentration doxycycline formulation (broad-spectrum antibiotic) delivered locally over 30 days.Portfolio Flagship Product: D-PLEX100 6 AdministrationApplied at the time of surgical closure, with dosing determined by the length of the surgical incision Regulatory statusBreakthrough Therapy, Fast Track, and QIDP designations, FDA 505(b)(2)
Page 7
7 Easily Applied in Any Surgical SettingD-PLEX100applied in abdominal surgery: Instruction for use:
Page 8
8 The Largest Phase III Trial for Prevention of SSI in Over a Decade PopulationPatients undergoing elective abdominal colorectal surgery with incision length > 20 cm Primary efficacy endpoint Reduction in SSI, mortality and reintervention within 30 days post index surgeryTrial sizeGlobal trial US, EuropeITT cohort: 798 patients
Page 9
9 Phenomenal Phase lll Clinical Trial Results 7142.6n=393 n=405(10.9%)(18.1%)40%reduction (p<0.005)Primary Efficacy Endpoint(ITT cohort) D-PLEX100+ SOCSoC* 3614.4 Surgical Site Infection (SSI) (ITT Cohort) n=377 n=391(3.8%)(9.5%)60%reduction (p<0.005)D-PLEX100+ SOCSoC*218D-PLEX100+ SOCSoC*n=377 n=391(2.0%)(5.6%)62%reduction (p<0.05)ASEPSIS Score >20(ITT Cohort)
Page 10
10 A Potential Multi-Million-Dollar Opportunity **Source IQVIA PM&I Global FlexView. Internal analysis 4.4M/YearAbdominal SurgeriesIncludes colorectal, gyn, urology, and high-risk procedures 12M/YearUS total addressable market in-patient surgical procedures
Page 11
11 Out-Licensing Go-To-Market Strategy Geographic Focus•U.S. first (largest SSI opportunity)•ROW: seeking partners in major markets Revenue Model•Upfront licensing fees•Milestones (Development, sales)•Royalties Ideal Sales Partners•Hospital-focused commercial footprint and P&T engagement experience•Specialty pharma with infectionprevention focus•MedTech manufacturers with strong surgical portfolio (e.g., sutures, surgical implants)
Page 12
Demonstrated Economic Incentive to Drive Adoption 12 D-PLEX100is eligible for NTAP program: up to 75% reimbursement of cost of drug Direct costSSI costs ~$30K/patient1on average•Prolonged length of stay and higher readmission rates•Re-operation in some cases (to debride and remove infected / necrotic tissues)Indirect costCMS 1-3% penalty on all the yearly Hospital Medicare reimbursementReputational costHospital SSI rates are public information and have direct influence on hospital ranking by CMS and U.S. News best hospitals ranking 1. Stone PW. Economic burden of healthcare-associated infections: an American perspective. Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):417-22.
Page 13
Surgeons perceive D-PLEX100to be more valuable overall than currently used interventions 13F/S – On Formulary & Stocked; F/NS = On Formulary, but NOT Stocked; NF/NS = Not on Formulary & Not Stocked Most Mentioned Patients Appropriate for D-PLEX100 Source: Indegene Market Research October 2025 Patient with a higher risk of infection immunocompromised, comorbidities, obese, uncontrolled diabetics, transplant patients Patients undergoing Colorectal Surgeries Any procedure with incisions >10 cm10%40%10%40%80%20% F / S F / NS How likely are you to prescribe D-PLEX100to prevent SSIs in eligible surgical patients? (% of responders) Extremely likely likely Not at all likely
Page 14
Pharmacy Directors expect high likelihood of formulary coverage and stocking of D-PLEX100 10% 10%90% 90%Likelihood for Formulary Coverage Likelihood for Stocking14 Extremely likelylikelyValue perception and likelihood for formulary coverage and stocking are high and grow even higher with the introduction of NTAPLikelihood of formulary converge and stocking of D-PLEX100(% of responders)
Page 15
Innovation Strategy 15 Surgical Site InfectionOncologyMetabolic Diseases& Obesity Our strategy is to leverage the power of our Kynatrix delivery platform to elevate treatment effectiveness Key Therapeutic Areas Collaborate with R&D partners to: Improve efficacy Extend molecule ½ life Eliminate systemic side effects and toxicity
Page 16
Innovation Pipeline 16
Page 17
Manufacturing Excellence Enabling Global Scale 17 PolyPid operates an 18,000 sq. ft., state-of-the-art GMP facility purpose-built for its proprietary Kynatrix drug-delivery technology. The site enables precise, reproducible production of our proprietary formulations and supports scalable manufacturing from clinical to commercial volumes, ensuring consistent product performance and global supply readiness.
Page 18
Always Delivering, Our Milestones Too 18 ✓CompletedPhase 3 Global SHIELD II Trial•Reached primary and all key secondary endpoints•~60 global clinical sites✓CompletedFull CMC & GMP ReadinessState-of-the-art 18,000 sq ft GMP manufacturing facility certified by Israel MoH & EU Qualified Person✓CompletedPre-NDA Interactions In a pre-NDA meeting minutes the FDA agreed that the clinical data package appears adequate to support NDA submission and review. FDA also agreed to a rolling NDA review ↓Q1 2026NDA Submission (US Market)↓H2 2026Submission for NTAP reimbursement ↓H2 2026 FDA acceptance letter and PDUFA Target date (eligible for priority review)↓H2 2026EU Submission↓Q1 2027FDA approval↓H2 2027 EU approvalExpected Timeline
Page 19
19 Financials Stock InformationNASDAQListingPYPDTicker$2.30-$5.1252-week range1 $100 MMarket cap1Share Structure19.0 MShares outstanding3.1 M Pre-funded warrants and shares held in abeyance 0.8 M @ $3.61 exercise priceWarrants 7.5 M @ $4.50 exercise priceWarrants 3.0 M @ $4.8 WAEPOptions outstanding Analyst coverage 1. As of February 6, 2026
Page 20
Built for Scale and Growth 20 Large, Attractive Market OpportunityAddressing a substantial global market of 7M+ surgeries annually, with significant unmet need in surgical site infection prevention.Multiple Near-Term CatalystsFDA submission Q1 2026Expected PDUFA date early 2027Innovation-Driven PipelineA growing pipeline built on PolyPid’s differentiated Kynatrix platform, enabling expansion into additional high-value indications beyond the lead program.
Page 21
!